Patents by Inventor Neil Lee Spector

Neil Lee Spector has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of Cancers Expressing p95 ErbB2
    Publication number: 20150190397
    Abstract: The truncated ErbB2 receptor (p95ErbB2) is shown to differ from the full-length ErbB2 receptor in its association with other ErbB receptors. The truncated receptor preferentially associated with ErbB3, whereas full length ErbB2 heterodimerizes with 5 either EGFR or ErbB3. Consistent with p95ErbB2 heterodimerization with ErbB3, it is shown that heregulin (an ErbB3 ligand) stimulates p95ErbB2 phosphorylation in breast cancer cell lines. Described herein are methods of identifying patients suitable for treatment with a p95ErbB2 inhibitor, and methods of treating such patients.
    Type: Application
    Filed: March 19, 2015
    Publication date: July 9, 2015
    Inventors: Neil Lee Spector, Wenle Xia
  • Treatment of Cancers Expressing p95 ErbB2
    Publication number: 20110020335
    Abstract: The truncated ErbB2 receptor (p95ErbB2) is shown to differ from the full-length ErbB2 receptor in its association with other ErbB receptors. The truncated receptor preferentially associated with ErbB3, whereas full length ErbB2 heterodimerizes with either EGFR or ErbB3. Consistent with p95ErbB2 heterodimerization with ErbB3, it is shown that heregulin (an ErbB3 ligand) stimulates p95ErbB2 phosphorylation in breast cancer cell lines. Described herein are methods of identifying patients suitable for treatment with a p95ErbB2 inhibitor, and methods of treating such patients.
    Type: Application
    Filed: September 30, 2010
    Publication date: January 27, 2011
    Inventors: Neil Lee Spector, Wenle Xia
  • Treatment of cancers expressing p95 ErbB2
    Patent number: 7829297
    Abstract: The truncated ErbB2 receptor (p95ErbB2) is shown to differ from the full-length ErbB2 receptor in its association with other ErbB receptors. The truncated receptor preferentially associated with ErbB3, whereas full length ErbB2 heterodimerizes with either EGFR or ErbB3. Consistent with p95ErbB2 heterodimerization with ErbB3, it is shown that heregulin (an ErbB3 ligand) stimulates p95ErbB2 phosphorylation in breast cancer cell lines. Described herein are methods of identifying patients suitable for treatment with a p95ErbB2 inhibitor, and methods of treating such patients.
    Type: Grant
    Filed: February 5, 2009
    Date of Patent: November 9, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: Neil Lee Spector, Wenle Xia
  • Predictive biomarkers in cancer therapy
    Patent number: 7794960
    Abstract: The use of various biomarkers to assess a subject's suitability for treatment with a EGFR/ErbB2 kinase inhibitor for a solid tumor are described. The biomarkers include TGFalpha, pS6, IGF-1R and levels of apoptosis occurring in tumor tissue.
    Type: Grant
    Filed: May 12, 2005
    Date of Patent: September 14, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: Neil Lee Spector, Albert Man
  • TREATMENT OF CANCERS EXPRESSING P95 ERBB2
    Publication number: 20090192189
    Abstract: The truncated ErbB2 receptor (p95ErbB2) is shown to differ from the full-length ErbB2 receptor in its association with other ErbB receptors. The truncated receptor preferentially associated with ErbB3, whereas full length ErbB2 heterodimerizes with either EGFR or ErbB3. Consistent with p95ErbB2 heterodimerization with ErbB3, it is shown that heregulin (an ErbB3 ligand) stimulates p95ErbB2 phosphorylation in breast cancer cell lines. Described herein are methods of identifying patients suitable for treatment with a p95ErbB2 inhibitor, and methods of treating such patients.
    Type: Application
    Filed: February 5, 2009
    Publication date: July 30, 2009
    Applicant: SMITHKLINE BEECHAM CORPORATION
    Inventors: Neil Lee Spector, Wenle Xia